Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling

CONCLUSIONS: A 4-week pre-GLP study supports the safety of inhaled FOS. A formal GLP assessment is underway to support a phase I clinical trial of an FOS DPI for LPR.LEVEL OF EVIDENCE: NA.PMID:38362183 | PMC:PMC10866582 | DOI:10.1002/lio2.1219

Source: Cancer Control - February 16, 2024 Category: Cancer & Oncology Authors: Alexandra Lesnick Tina L Samuels Donna Seabloom Beverly Wuertz Abhilash Ojha Davis Seelig Frank Ondrey Timothy S Wiedmann Chris Hogan Emma Torii Hui Ouyang Ke Yan Guilherme J M Garcia Jonathan M Bock Nikki Johnston Source Type: research